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Rationale: Although lower airway (LAW) infection with bacteria like P. aeruginosa
(P.a.) is the leading cause of morbidity in CF, dynamics of acquisition and
persistence are not sufﬁciently understood. Recently, the upper airways (UAW)
were shown to harbour the same clones of P.a. and S. aureus compared to the LAW.
Therefore, a longitudinal analysis of the dynamic process of colonization will be
of major interest.
Objectives: Aims of the study were non-invasive assessment of acquisition and
persistence of pathologic bacteria in UAW and LAW of patients of all ages within
CF-routine care.
Methods: 80 CF patients were evaluated longitudinally (max. 48 months). LAW
preferably were sampled by expectorated sputum and UAW by nasal lavage. Single
nucleotide polymorphisms of P.a.-strains from both segments were compared.
Results: 16 patients revealed new airway colonisation with P.a. In 4 of them (25%),
P.a. simultaneously was detected in LAW and UAW samples. So far, one patient
harboured P.a. in the UAW in two nasal lavages but never in LAW-samples. Also,
a lung-transplanted patient revealed P.a. only in the UAW, which was identical to
strains from UAW and LAW previous to LTX. MRSA was detected for the ﬁrst
time in the UAW of one patient.
Conclusions: Additional UAW-sampling provides new insights into the dynamics
of bacterial acquisition into CF-airways: relevant ﬁndings regarding therapy and
segregation may not be detected following current best standards of care. Thus, our
data challenge the need to include UAW-assessment into the scientiﬁc and clinical
focus of CF-care.
256* Synchronisation of intravenous (IV) antibiotic and in vitro
susceptibility of sputum Pseudomonas aeruginosa (PA) does not
inﬂuence outcome of care of adult CF patients – a prospective
study
I. Sequeiros1, R. Westley1, K. Levitt1, N.A. Jarad1. 1Bristol Adult CF Centre,
Bristol, United Kingdom
Background: In this prospective study, we researched if synchronization of antibi-
otic and in vitro susceptibility of sputum PA inﬂuences outcome measures of adult
CF patients.
Patients and Methods: We studied 41 acute pulmonary exacerbations (PEx) in
30 adult CF patients (17 male, mean age 25.8 y). PEx was regarded as present if
patients presented with increase in symptoms deemed to be sufﬁcient to start IV
treatment.
Antibiotics were prescribed based on previous sputum PA sensitivities and previous
successful antibiotic combination. Synchronisation between PA sensitivities of the
PEx sputum and the antibiotics prescribed were classiﬁed as group 1 – little or no
synchronisation (13 PEx), group 2 – partial synchronisation (16 PEx) and group
3 – complete synchronisation (12 PEx).
FEV1, FVC and symptom score (SS) were recorded at the start and on day 14
of IV treatment. SS consisted of the sum of scores of the CF symptoms: cough,
sputum, breathlessness and fatigue. Each symptom was scored from 1−4, 4 being
the worst. The number of days till the next PEx was also recorded.
Results: The baseline characteristics for age and spirometry of the 3 groups were
comparable. Synchronisation rate did not inﬂuence the change of spirometry values
or SS at the end of treatment. The time until next PEx (mean, SD) for group 1 was
(104, 75.5 days), for group 2 (84.8, 49.6 days) and for group 3 (97, 8.50 days).
Conclusions: This prospective study provides further evidence that synchronisation
of IV antibiotics and in vitro susceptibility of sputum PA does not inﬂuence any
measurable parameter of PEx. The choice of antibiotic in any PEx needs to be
made on parameters other than the conventional sensitivity results.
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Background: After years of chronic pulmonary infection, many CF patients
need lung transplantation (LTX). The most common pathogen is Pseudomonas
aeruginosa, but many patients harbour A. xylosoxidans or Burkholderia multivorans.
We wanted to compare the clinical course leading to LTX in these patients.
Methods: LTX recipients from the Copenhagen CF centre in the last 10 years
were included. Age, cause and duration of chronic infection, increase in levels of
precipitating antibodies during chronic infection, and change in FEV1 for 5 years
prior to LTX were studied. One way Anova was used for comparison.
Results: 27 patients were included, 17 with P. aeruginosa, 5 with A. xylosoxidans
and 5 with B. multivorans. Table 1 shows demographic data. No differences in age
or change in FEV1 were found. Chronic infection duration was shorter in the A.
xylosoxidans and the B. multivorans group compared to the P. aeruginosa group.
Level of precipitins increased most rapidly in the A. xylosoxidans group.
Conclusion: Chronic, pulmonary A. xylosoxidans infection is an important aetiol-
ogy to end-stage lung disease.
Supported by: Danish CF foundation.
Demographic data
A. xylosoxidans B. multivorans P. aeruginosa p-value
Age at LTX (years) 27.6 (18.8, 33.5) 32.7 (22.1, 50.9) 33.1 (24.1, 43) n.s.
Duration of infection (years) 6.4 (5.7, 12.2) 8.4 (5.6, 18.3) 26.3 (12.9, 33.8) <0.001
Change in precipitins pr. year 2.8 (2.4, 6.1) 2 (1.9, 3.6) 1.4 (0.7, 2.6) <0.001
Change in FEV1 (5 years) −16.3 (−45.5, −11.9) -16.4 (−18, −8.5) -14 (−30.9, −2.7) n.s.
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Objectives: To assess bacterial colonization in patients with cystic ﬁbrosis identiﬁed
by newborn screening.
Methods: Thirty-one cystic ﬁbrosis children were diagnosed by immunoreactive
trypsine plus sweat test between 2003 and 2006. All patients received regular
treatment at the Cystic Fibrosis Clinic, Federal University of Minas Gerais, Brazil.
Cultures of tracheal aspiration were realized in all visits and their results were
analyzed retrospectively.
Results: Among the 31 children identiﬁed by newborn screening, 28 (90.3%) were
included in this study. The remaining 3 patients had no culture records. Median age
was 2.3 years, 50% were females. S. aureus was identiﬁed in 26 patients (92.9%)
in at least one culture. The median age for the ﬁrst colonization of S. aureus was
77 days and almost half of the children (42.9%) had positive cultures in the ﬁrst
month of life. 22 patients (78.6%) had 3 or more positive cultures for S. aureus and
the median age for the third isolation was 9.5 months. Oxacillin-Resistant strains
were identiﬁed in two patients. P. aeruginosa was isolated in at least one culture of
14 children (50%). The median age for the ﬁrst positive culture was 14 months and
the lowest age was 76 days. Two patients ﬁlled the criteria for chronic colonization
and the median age for the third isolation was 17 months. Mucoid strains were not
identiﬁed. B. cepacia was identiﬁed in one patient.
Conclusions: Age of the ﬁrst colonization of S. aureus and P. aeruginosa was very
early in this group of children diagnosed by newborn screening, despite the hygienic
measures routinely applied. In order to reduce possible crossover contamination,
other measures were implemented.
